This regimen is not immediately applicable in the developing world. Drug costs are very high, and because many women do not attend for antenatal care or deliver in hospital much of the protocol is impractical; it is also unsafe to advocate widespread avoidance of breastfeeding [3] . Thus, trials are underway to test short regimens of various antiretroviral drugs to determine whether an effective but cheaper and less complex protocol can be used in resource-poor settings.
Some richer developing countries, such as South Africa, are considering how antiretrovirals might be made available to HIV-infected pregnant women, and the manufacturer of ZDV (Glaxo-Wellcome, Stevenage, UK) is reported to be considering whether to offer ZDV at reduced cost to governments in subSaharan Africa. However, provision of antiretrovirals in pregnancy is not just a cost issue, and capacity to implement also needs very careful consideration. Using data from a health district in South Africa, we asked whether providing antiretrovirals to pregnant women is likely to be cost-effective, affordable, and implementable.
Methods

Setting and HIV epidemic
Hlabisa health district, situated in northern KwaZulu/Natal is largely rural, and is home to approximately 210 000 Zulu-speaking people. The economy is based on migrant worker remittances, pensions and subsistence farming. In 1994, per capita income was US$ 1730, the literacy rate was 69%, and life expectancy was 63 years (Economic Research Unit, University of Natal, Natal, South Africa). Antenatal care is provided almost exclusively by midwives at the district hospital and its 12 community clinics. Each clinic has at least three midwives (most professional nurses are trained midwives in South Africa) and six have nurses trained as HIV/AIDS counsellors. In a recent household survey (unpublished), 86% of mothers had breastfed their last child and 60% had done so for at least 12 months.
HIV prevalence in women attending antenatal clinics in Hlabisa increased rapidly from 4.2% in 1992 [4] to 26.0% in 1997 (unpublished). HIV prevalence among 268 children admitted to the paediatric medical service of the district hospital was 25.6% in 1997 (unpublished data). The impact of the epidemic on the service is already substantial: for example, the annual tuberculosis caseload increased from 312 in 1991 to 1250 in 1996, and the number of AIDS cases is rising rapidly.
Steps required to reduce vertical transmission
If antiretrovirals are to be provided with maximal public health impact in the district, several distinct steps are required (Table 1) .
First, as many pregnant women as possible must attend for antenatal care, and as early as possible. ZDV has only been shown to be effective when started before the 34th week of gestation [2] , although it seems likely that antiretrovirals will be effective when given late in pregnancy [5] . Second, as many women as possible must be counselled about the potential intervention and tested for HIV infection. Currently in Hlabisa, trained HIV counsellors are only available in half the district clinics and HIV testing is carried out in Durban, 300 km away. Third, as many women as possible must receive and adhere to the intervention. Fourth, as many women as possible must deliver either in the hospital or clinic, so that intrapartum antiretrovirals can be administered (intravenously or orally). In Hlabisa, a 24 h maternity service is available in half the district clinics as well as the hospital. Fifth, risk from breastfeeding should be minimized. Breastfeeding contributes around 30% [6] of the risk of vertical transmission, depending on the proportion that breastfeed and the duration of breastfeeding. Finally, paediatric follow-up is important to encourage adherence with neonatal therapy, to provide support, and in order to assess the impact of the intervention, the mother-child pair require regular assessment. It may be important to determine early in the post-natal period whether the intervention has been successful in order to guide decisions on feeding practice, and because the parents are likely to want to know.
Effectiveness of possible intervention scenarios
We considered three possible scenarios under which antiretrovirals might be made available in the district (scenarios A, B and C), and compared their effectiveness with no intervention.
No intervention
From health service records and a community survey [7] , we estimated that 8421 women in the district fall pregnant each year, and that 8000 (95%) attend for antenatal care. Of the 8421 pregnant women in 1997, 26% (n = 2189) were assumed to be HIV-infected, and assuming a 30% vertical transmission rate (VTR) [1, 6] , under a no intervention scenario, 657 paediatric HIV infections were projected for 1997.
Assumptions
Scenario A In scenario A, the ACTG 076 protocol (with breastfeeding allowed) is provided through existing health service infrastructure (Table 1) .
Of the 421 (5%) pregnant women who do not attend for antenatal care ( Fig. 1 ), 109 (26%) are assumed to be HIV-infected and to experience a 30% VTR. Of the remaining 8000 women, 10% attend their first antenatal visit later than 34 weeks gestation and are not eligible for ZDV. Again, 26% (n = 208) are assumed to be HIV-infected and the VTR is estimated as 30%. Of the remaining 7200, 1872 (26%) are HIV-infected and are eligible for ZDV. However, it is unlikely that all of these women would receive a full course of ZDV.
Although acceptance of HIV testing in the clinical setting in Hlabisa is generally high (e.g., around 90% among patients with tuberculosis [8] ) not all patients receive their results. Of 664 general ward patients tested between October 1995 and January 1996, at a time when specimens were sent to a referral laboratory 300 km away, only 17% received their results and were post-test counselled [9] . These operational difficulties are not limited to HIV testing. In a study of syphilis among pregnant women, only 49% of those with a positive rapid plasma reagin test received results and completed a full course of treatment [10] . Although there is currently no capacity or effort to individually pre-test counsel each woman, we assumed that women would be informed of the intervention in groups, and that 35% (approximately midway between 17% and 49%) would receive results and ZDV therapy. The remaining 65% would not receive ZDV.
How effective might ZDV be under these circumstances? Due to almost universal and prolonged breastfeeding, we estimated that ZDV would reduce the VTR by 50% (from 30 to 15%) instead of 67.4%, as measured in ACTG 076.
Scenario B
In scenario B, substantial efforts are made to enhance service infrastructure with the aim of improving ZDV provision and delivery (Table 1) . ZDV is again provided according to the ACTG 076 protocol. Enhancements include widespread community health promotion to encourage early attendance for antenatal care and to inform the community about the intervention available, on-site HIV testing, extra staff to provide counselling capacity, an assured drug supply, extra staff to provide of a 24 h maternity service in all clinics, and selective avoidance of breastfeeding.
When on-site HIV testing was introduced in Hlabisa, the proportion of patients post-test counselled increased to 96% [9] , and on-site syphilis testing increased the proportion fully treated to 75% (unpublished data).
We assumed that health promotion is successful such that only 2.5% of pregnant women do not attend for antenatal care and that only 2.5% of those that attend do so later than 34 weeks of gestation and are hence ineligible for ZDV (Fig. 1) . Of the remaining 8005 women, 2081 (26%) are assumed to be HIV-infected. Due to the on-site HIV testing and increased counselling capacity we assumed that 75% accept testing, receive the result and receive the intervention. The VTR is assumed to be 12.5% (58% reduction). The remaining 25% would not receive ZDV and would experience a 30% VTR.
Scenario C
One of the trials of alternative antiretroviral regimens is underway in Durban, South Africa and is testing a combination of ZDV and lamivudine: ZDV 300 mg twice daily plus lamivudine 150 mg twice daily to the mother from 36 weeks gestation for 4 weeks; ZDV 300 mg every 3 h and lamivudine 150 mg every 12 h during labour; ZDV 300 mg twice daily for 1 week and lamivudine 150 mg twice daily to the mother for 1 week postpartum; and ZDV 4 mg/kg twice daily and lamivudine 2 mg/kg twice daily to the infant for 1 week. Here, we assumed that this multidrug regimen is more effective than ZDV alone (60% reduction in VTR to 12%) and that more women accept and complete treatment (80%) because it is a shorter regimen (Fig. 1) . We also assumed the same enhancements of service capacity and infrastructure as in scenario B.
Intervention costs
The cost analysis was undertaken from the perspective of the health system. Each intervention component was calculated individually. Drug costs were based on recent market prices and were calculated using the mean age of gestation at the first antenatal visit. Staff costs were based on gross salary figures. Training costs were calculated using recent data from Hlabisa, and health promotion costs were extrapolated from a recent sexually transmitted disease (STD) health education initiative. Estimates of increased counselling capacity requirement was based on the results of discussions with the district AIDS team, assuming that women would be pre-test counselled in a group but individually post-test counselled at each antenatal clinic visit and after delivery. Increased capacity required to deliver more women in clinic or hospital was estimated in discussion with the nursing manager of the maternity service. Follow-up costs assumed HIV enzyme-linked immunosorbent assays at age 15-18 months, and clinic visits scheduled to coincide with existing under 6-year clinic visits. The costs of HIV testing were based on existing quotes. We also assumed that one extra laboratory technician would be needed to supervise and help with the on-site HIV testing, as well as resolving indeterminate results. Costs are reported in US$ and were calculated at an exchange rate of 4.7 South Africa Rand per US$ 1 (November 1997).
Calculation of cost-effectiveness
Cost data were combined with estimates of effectiveness to calculate the cost per infection prevented. The cost per potential life-year gained was then calculated using a life expectancy of 63 years, discounted at both 3 and 6% to allow comparison with other recent economic analyses of public health interventions in developing countries. These values were chosen because 3% was the rate used by the World Bank in 1993 [11] and 6% has been used in recent economic analyses of important public health interventions in developing countries [12] . A sensitivity analysis was undertaken to determine the effect of a substantial reduction (to 10% of current costs) in drug costs on cost-effectiveness.
Results
With the no intervention scenario, 657 paediatric HIV infections were projected to occur in 1997.
In scenario A (Fig. 1 
Costs
The total cost of scenario A was estimated at US$ 574 825, scenario B at US$ 1 520 770, and scenario C at US$ 764 901. These values represent approximately 11, 28 and 14% of the current total district health budget (US$ 5.3 million), respectively.
The costs of the individual components of each intervention are shown in Tables 2 and 3 . Costs of drugs were the most significant item, accounting for US$ 561 279 (97.6%) of the total cost of scenario A, US$ 1 337 644 (87.9%) in scenario B, and US$ 581 106 (75.9%) in scenario C. Most of the remaining cost was on salaries for new staff.
Cost-effectiveness
The cost per paediatric HIV infection prevented ranged from US$ 5806 in scenario A to US$ 2492 in scenario C (Table 4) . Discounted at 3%, the cost per potential life-year gained was US$ 205 in scenario A and US$ 88 in scenario C. These values were much lower (US$ 25 and 28, respectively) if drug costs are assumed to be 10% of current costs.
Capacity
The district AIDS team estimated that eight extra nurse counsellors would be required to provide group pre-test counselling and repeated individual post-test counselling to the approximately 150 women attending for antenatal care each week across the district. These counsellors would be allocated to the busier clinics and the hospital, and would provide leave and sickness relief for their colleagues. Only the smaller clinics would not require extra counsellors. Four additional midwives would be required to provide a 24 h maternity service in all clinics and to cope with the extra caseload. An additional laboratory technician would be required in addition to the two current staff who had no spare capacity.
Discussion
These data suggest that providing short-course combination antiretrovirals to pregnant women in rural South Africa may be a cost-effective intervention. However, because it would entail a substantial increase in the health budget and because its implementation would pose serious challenges, it is questionable whether it is a realistic public health intervention. The major cost item is drugs. Drug costs must fall dramatically for the intervention to become substantially cheaper. If a short regimen is found to be effective, the intervention will be cheaper, more cost-effective, and easier to implement than the ACTG 076 protocol. However, provision of antiretrovirals to pregnant women in the developing world is not just a cost issue [13] , as the capacity to implement also needs to be addressed.
The aim of providing antiretrovirals in pregnancy is to reduce the impact of HIV on infant and childhood mortality. How likely is it to succeed? The infant mortality rate (IMR) in Hlabisa 5 years ago was around 65 per 1000 live births (unpublished), equating to about 520 deaths amongst approximately 8000 babies born each year. Of the 657 children that acquire paediatric HIV infection with no intervention, if we assume 20% die in the first year of life, IMR will increase by 25% to 81 per 1000. Even in the presence of an effective intervention such as scenario C, the IMR would still increase by 9% to 71 per 1000. Furthermore, in settings with high HIV incidence, substantial numbers of women will acquire HIV infection while breastfeeding. Risk of vertical transmission from breastfeeding during primary HIV infection has been estimated at 29% [14] , and this would increase IMR by a further 10% in Hlabisa (data not shown). Short-course peripartum antiretrovirals do not protect against this risk and therefore existing strategies to prevent HIV infection among women should also be strengthened in addition to providing antiretrovirals. Modified feeding practice with formula feeding replacing breastfeeding would strengthen an antiretroviral intervention in settings where IMR due to diarrhoeal disease is relatively low [3] .
How does the cost-effectiveness of this intervention compare with others? At US$ 2492 per infection averted and US$ 88 per potential life-year gained, it compares only reasonably with established health interventions: for example, childhood immunization costs around US$ 20 per disability-adjusted life-year (DALY) saved and oral rehydration solution costs US$ 25-75 [11] . The STD intervention in Mwanza that was associated with a reduced HIV incidence of around 40% cost US$ 10 per DALY. The cost per potential life-year gained can be usefully compared with cost per DALY because the intervention averts mortality rather than morbidity, and thus one life-year gained does not need to be adjusted for disability (as would an intervention averting morbidity). Although perinatal interventions are particularly attractive because they offer the opportunity to gain many more life-years than interventions later in life, many babies saved by antiretroviral therapy will become orphans within impoverished families, and these children may not thrive and survive as well as HIV-uninfected children of HIV-uninfected mothers. Longitudinal studies, including the DALY as a measure of effectiveness, with detailed costing are required to clarify the true net long-term benefit of providing antiretroviral therapy in pregnancy. We did not consider care cost for HIVinfected children that might be saved by this intervention because no accurate data exists for this from Africa; however, any costs saved would make antiretroviral therapy a more cost-effective intervention. In South Africa, costs of caring for HIV-infected children are little different from HIV-uninfected children, because antiretrovirals are not available outside the private sector. Incremental costs are important (Table 5) because they indicate the additional amount to be spent for a given benefit, and these data confirm the costeffectiveness of this intervention.
What is the feasibility of providing antiretrovirals as a public health intervention in South Africa and the rest of sub-Saharan Africa? Staffing and infrastructure, even in the least developed parts of South Africa are far in advance of those in much of the rest of the subcontinent. Even so, current capacity to deliver antiretrovirals effectively is severely limited, and we estimate that without substantial improvements only about 14% of expected paediatric HIV infections could be averted. Innovative approaches may ease implementation. For example, could group counselling by lay people replace individual counselling by nurses? In settings where most women deliver under health worker supervision, adding oral antiretrovirals to a delivery schedule may not stretch the system too far, but substantial postpartum counselling, support and instruction will also be required and this will inevitably require more staff. Where will the extra staff required come from? What of countries where women frequently deliver at home?
The public health impact of antiretrovirals will be limited unless most women are drawn into the system, and that system must function. We have not considered the costs or impact of selective avoidance of breastfeeding due to the uncertainties around it, but this is an important issue that requires further research. Furthermore, an antiretroviral intervention could be strengthened by a broader effort to improve maternity services in high HIV prevalence settings, and an integrated package perhaps including vaginal lavage [15] and simple modifications to obstetric care might be appropriate. The possible roles of vitamin A and caesarean section require further study. Developing the capacity to deliver antiretrovirals could be seen as an important opportunity to develop health services in resource-poor settings.
It is inevitable that effectiveness in the programme setting will not mirror that achieved in trials. In the United States in 1996, only 67% of HIV-infected women received ZDV. Between 1994 and 1996 the VTR amongst those receiving ZDV was 12% (it was 8.3% in the ACTG 076 trial) compared with 30% amongst those who did not receive ZDV. Nevertheless, there has been a substantial and sustained decline in paediatric AIDS cases as a result [16] . The effectiveness figures we have calculated for Hlabisa represent the best-case scenario, which might be difficult to achieve under programme conditions.
Health systems in developing countries are under severe financial pressure. How then can such an expensive intervention ever be affordable? A large increase in health expenditure to fund widespread use of antiretroviral therapy in pregnancy seems unlikely. Even in South Africa, which is relatively resource-rich, an increase in district budget of 14% is unlikely within current budgetary constraints. What other funding mechanisms exist?
It is possible that manufacturers might reduce drug costs considerably, and this would make the intervention much more attractive to donors. Companies may even underwrite some of the infrastructure and training costs required for implementation. Scope may also exist for some internal redistribution of resources, but this is often difficult within bureaucratic health systems whose major expenditure is on salaries. Although reasonably cost-effective, this intervention is extremely expensive because it must be applied to large numbers of people to have a substantial public health impact.
Provision of antiretroviral therapy to pregnant HIVinfected women in South Africa and other parts of the subcontinent offers potential to reduce the inevitable increase in infant and childhood mortality that accompanies the HIV epidemic. However, any intervention will be very expensive, largely because of very high drugs costs. Whether it is feasible at all depends on local circumstances. It seems unlikely that a country-wide programme could be instituted, even in South Africa, within a short time. Careful operational research is required before large-scale implementation is contemplated. Finally, politicians and health service managers will need to determine what priority is afforded to the reduction of vertical transmission of HIV at a time when there are many competing health needs and constrained budgets. 
